Mitochondrial membrane potential of CD4⁺ cells in patients with mild bronchial asthma exposed to atmospheric particulate matter

Introduction. The pathogenesis of bronchial asthma largely depends on changes in the cells’ energy state, in which the mitochondrial membrane potential (MMP) plays a major role. A decrease in MMP is evident at the early stages of asthma development and may be one of the key pathological signs of the disease. The course and progression of asthma can be aggravated by various factors, including airborne particulate matter (PM). However, information on MMP changes in individual lymphocyte subpopulations under PM exposure is scarce.
Aim. To establish disturbances in the mitochondrial membrane potential of CD4+ cells in patients with mild asthma under the influence of ground-level atmospheric particulate matter.
Materials and methods. This in vitro study included 131 patients with asthma and 60 apparently healthy individuals. Model suspensions simulating the multicomponent pollution of Vladivostok air were used as a challenge. MMP levels (MMP-1 – MMP-5) were determined by flow cytometry, and the MMP coefficient (cMMP) was calculated.
Results. In asthma the main shifts occurred at MMP-1, MMP-2 and MMP-3 levels: the proportion of cells with high MMP decreased, whereas that of cells with moderately reduced MMP (MMP-2 and MMP-3) increased. PM exposure induced significant redistribution of MMP levels in asthma patients. Lower disease control was associated with more pronounced energy disturbances: in controlled versus partially controlled asthma, cMMP was 82.9% lower. Under PM exposure, cMMP fell by 27.2% and 16.3% in controlled and partially controlled asthma, respectively, compared with unexposed groups.
Conclusion. The study reveals features of CD4+-cell MMP impairment in mild bronchial asthma under atmospheric PM exposure, depending on disease-control level. Assessing MMP-level redistribution and the cMMP as an integral indicator of CD4+-cell energy status may facilitate early detection of energy-metabolism disorders in asthma and help optimise prevention of disease progression.

1. Asher M.I., Rutter C.E., Bissell K., Chiang C.Y., El Sony A., Ellwood E., Ellwood P., Garcia-Marcos L., Marks G.B., Morales E., Mortimer K., Perez-Fernandez V., Robertson S., Silverwood R.J., Strachan D.P., Pearce N.; Global Asthma Network Phase I Study Group. Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study. Lancet 2021; 398(10311):1569–1580. https://doi.org/10.1016/S0140-6736(21)01450-1

2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (Update 2024). Available at: https://ginasthma.org/

3. Mortimer K., Lesosky M., Garcia-Marcos L., Asher M.I., Pearce N., Ellwood E., Bissell K., El Sony A., Ellwood P., Marks G.B., Martkinez-Torres A., Morales E., Perez-Fernandez V., Robertson S., Rutter C.E., Silverwood R.J., Strachan D.P., Chiang C.Y.; Global Asthma Network Phase I Study Group. The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study. Eur. Respir. J. 2022; 60(3):2102865. https://doi.org/10.1183/13993003.02865-2021

4. Farraia M., Cavaleiro Rufo J., Paciencia I., Castro Mendes F., Delgado L., Laerte Boechat J., Moreira A. Metabolic interactions in asthma. Eur. Ann Allergy Clin. Immunol. 2019; 51(5):196–205. https://doi.org/10.23822/EurAnnACI.1764-1489.101

5. Herrera-De La Mata S., Ramirez-Suastegui C., Mistry H., Castañeda-Castro F.E., Kyyaly M.A., Simon H., Liang S., Lau L., Barber C., Mondal M., Zhang H., Arshad S.H., Kurukulaaratchy R.J., Vijayanand P., Seumois G. Cytotoxic CD4+ tissue-resident memory T cells are associated with asthma severity. Med. 2023; 4(12):875–897.e8. https://doi.org/10.1016/j.medj.2023.09.003

6. Jeong J., Lee H.K. The role of CD4+ T cells and microbiota in the pathogenesis of asthma. Int. J. Mol. Sci. 2021; 22(21):11822. https://doi.org/10.3390/ijms222111822

7. Cloonan S.M., Choi A.M. Mitochondria in lung disease. J. Clin. Invest. 2016; 126(3):809–820. https://doi.org/10.1172/JCI81113

8. Bhatti J.S., Bhatti G.K., Reddy P.H. Mitochondrial dysfunction and oxidative stress in metabolic disorders – a step towards mitochondria based therapeutic strategies. Biochim. Biophys. Acta Mol. Basis Dis. 2017; 1863(5):1066–1077. https://doi.org/10.1016/j.bbadis.2016.11.010

9. Golokhvast K.S., Panichev A.M., Gulkov A.N., Chaika V.V. Patent 2525427 RU. [Method for preparing standard aerosol samples]; published 10.08.2014 (in Russian).

10. Veremchuk L.V., Vitkina T.I., Barskova L.S., Gvozdenko T.A., Mineeva E.E. Estimation of the size distribution of suspended particulate matters in the urban atmospheric surface layer and its influence on bronchopulmonary pathology. Atmosphere 2021; 12(8):1010. https://doi.org/10.3390/atmos12081010

11. Hou T., Zhu L., Wang Y., Peng L. Oxidative stress is the pivot for PM2.5-induced lung injury. Food Chem. Toxicol. 2024; 184:114362. https://doi.org/10.1016/j.fct.2023.114362

12. International statistical classification of diseases and related health problems 10th revision. 2016. Available at: https://mkb-10.com/

13. Kondratyeva E.V., Vitkina T.I., Veremchuk L.V. [Atmospheric ground layer pollution by suspended solid particles in areas with different technogenic loads]. Bûlleten' fiziologii i patologii dyhaniâ = Bulletin Physiology and Pathology of Respiration 2024; 91:68–76 (in Russian). https://doi.org/10.36604/1998-5029-2024-91-68-76

14. Vitkina T.I., Kondrateva E.V., Mineeva E.E., Gvozdenko T.A. Patent 2835342 RU. [Method for predicting exacerbations of mild to moderate bronchial asthma]; published 24.02.2025 (in Russian).

15. Suprun E.N. [Assessment of the membrane potential of mitochondria in immunocompetent blood cells of children with asthma, depending on controllability of the course of the disease]. Bûlleten' fiziologii i patologii dyhaniâ = Bulletin Physiology and Pathology of Respiration 2022; 86:50–55 (in Russian). https://doi.org/10.36604/1998-5029-2022-86-50-55

16. Kondratyeva E.V., Vitkina T.I. [Functional state of mitochondria in chronic respiratory diseases]. Bûlleten' fiziologii i patologii dyhaniâ = Bulletin Physiology and Pathology of Respiration 2022; 84:116–126 (in Russian) https://doi.org/10.36604/1998-5029-2022-84-116-126

17. Zhou W.C., Qu J., Xie S.Y., Sun Y., Yao H.W. Mitochondrial dysfunction in chronic respiratory diseases: implications for the pathogenesis and potential therapeutics. Oxid. Med. Cell Longev. 2021; 2021:5188306. https://doi.org/10.1155/2021/5188306

18. Denisenko Y.K., Novgorodtseva T.P., Vitkina T.I., Antonyuk M.V., Bocharova N.V. [The fatty acid composition of the mitochondrial membranes of platelets in chronic obstructive pulmonary disease]. Klinicheskaya meditsina = Clinical medicine 2018; 96(4):343–347 (in Russian). https://doi.org/10.18821/0023-2149-2018-96-4-343-347

19. Kondrateva E.V., Vitkina T.I. [Impact of air microtoxicants on the blood cells energy state in bronchial asthma]. Dal′nevostochnyy meditsinskiy zhurnal = Far Eastern Medical Journal 2024; 2:30–33 (in Russian). http://dx.doi.org/10.35177/1994-5191-2024-2-5